Company: TAK
Filing Date: 2025-12-08
Form Type: 6-K
Source: 0001395064-25-000164
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-12-08
Form: 6-K
Chunk 1
---

Delivers Durable Response and Hematocrit Control in Polycythemia Vera</div>

#### OSAKA, Japan, December 8, 2025 –
Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced on December 6, 2025 (ET), that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition. For further details, please refer to the attached press release.

The topline results of this study were announced on March 3, 2025, in “Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera”. In addition, “Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera” was announced on June 2, 2025.

| Media Contact:        |     | Investor Contact:              |
| Emy Gruppo            
 emy.gruppo@takeda.com |     | Christopher O’Reilly           
 christopher.oreilly@takeda.com |

The impact on Takeda’s financial results for the fiscal year ending March 31, 2026 (FY2025), following the study results, is immaterial.

<div align='center'>###</div>

News Release

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

− 52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals

− These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints

− Patients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response